- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| Do | Radiopharm Theranostics stock initiated with buy rating at H.C. Wainwright | 1 | Investing.com | ||
| Mi | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mi | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | - | ASX | ||
| 01.05. | RADIOPHARM THERANOSTICS LIMITED: Financial Services and Company Secretary Changes | - | ASX | ||
| 23.04. | Radiopharm Theranostics Reports Business Update | 272 | GlobeNewswire (Europe) | Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI... ► Artikel lesen | |
| 23.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 20.04. | Radiopharm presents early data on HER2-targeted cancer therapy | 1 | Investing.com | ||
| 19.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Initial Findings from Phase 1 177Lu-RAD202 Trial | - | ASX | ||
| 16.04. | Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases | 244 | GlobeNewswire (Europe) | Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial... ► Artikel lesen | |
| 16.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.04. | RADIOPHARM THERANOSTICS LIMITED: RAD Completes Enrollment in Phase 2b Trial of RAD 101 | - | ASX | ||
| 08.04. | Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial | 310 | GlobeNewswire (Europe) | SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 08.04. | RADIOPHARM THERANOSTICS LIMITED: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 | 1 | ASX | ||
| 07.04. | Radiopharm schließt Liefervertrag mit Siemens Healthineers für Hirntumor-Diagnostikum | 79 | Investing.com Deutsch | ||
| 07.04. | Radiopharm signs supply deal with Siemens for brain cancer drug | 14 | Investing.com | ||
| 07.04. | Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101 | 33 | RTTNews | ||
| 07.04. | Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. | 773 | GlobeNewswire (Europe) | Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures... ► Artikel lesen | |
| 07.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.04. | RADIOPHARM THERANOSTICS LIMITED: RAD and Siemens Sign Clinical Supply Agreement for RAD101 | - | ASX |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Opening Bell: Bitcoin, Strategy, Broadcom, Marvell, Micron, Axon Enterprise, Moderna, Lululemon | Die US-Börsen haben am Donnerstag eine zweigeteilte Entwicklung gezeigt. Der Dow Jones eröffnete mit klaren Gewinnen, baute diese im Verlauf deutlich aus und schloss 1,73 Prozent fester. Der Nasdaq... ► Artikel lesen | |
| VALNEVA | 2,331 | -0,64 % | Valneva im Höhenflug: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| PALATIN TECHNOLOGIES | 14,200 | +3,65 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,210 | +0,83 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,240 | -4,26 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,690 | +0,27 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| XOMA ROYALTY | 36,200 | -1,09 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,580 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones | OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program... ► Artikel lesen | |
| NOVOCURE | 15,175 | +11,05 % | NovoCure Ltd - 8-K, Current Report | ||
| PHARMING | 1,115 | +0,54 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| CYTOKINETICS | 63,00 | +1,58 % | Cytokinetics, Incorporated: Cytokinetics bringt MYQORZO (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland | Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa
SOUTH SAN FRANCISCO, Kalifornien, und ZUG, Schweiz, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:... ► Artikel lesen | |
| TRAWS PHARMA | 1,380 | +0,73 % | Traws Pharma, Inc.: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a... ► Artikel lesen |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,23 % bei einem Aktienkurs von 4,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.